Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

1-methylnicotinamide for the treatment of diseases associated with c-reactive protein

A disease, 1-MNA technology, applied in the direction of resistance to vector-borne diseases, skin diseases, bone diseases, etc., can solve problems such as restrictions on the use of niacin

Inactive Publication Date: 2019-04-02
法米娜生物技术公司
View PDF26 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the use of niacin is limited due to dose-dependent side effects including dyspepsia, abdominal pain, diarrhea, and especially flushing
In addition, niacin is contraindicated in patients with liver disease and should not be used in patients with unstable angina or acute myocardial infarction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 1-methylnicotinamide for the treatment of diseases associated with c-reactive protein
  • 1-methylnicotinamide for the treatment of diseases associated with c-reactive protein
  • 1-methylnicotinamide for the treatment of diseases associated with c-reactive protein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0096] Treatment with 1-MNA chloride reduces blood or serum CRP levels

[0097] Research design

[0098] The study was a randomized, double-blind, placebo-controlled, mandatory dose-escalation multicenter study.

[0099] standard constrain

[0100] ·At the time of signing the informed consent, the patient is at least 18 years old and ≤80 years old;

[0101] • Women of childbearing potential must have a negative urine pregnancy test at Screening and Visit 4. A woman is considered not of childbearing potential if she meets the following conditions:

[0102] a. Hysterectomy or tubal ligation was performed before the first visit;

[0103] b. Menopause, defined as 12 months without menstruation or FSH level within the menopausal range;

[0104] Women of reproductive potential must agree to use effective birth control throughout the study. Acceptable methods of birth control include: implantable contraceptives, injectable contraceptives, oral contraceptives, transdermal contra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The use of 1-MNA or a pharmaceutically acceptable salt thereof for reducing the risk of cardiovascular disease in a subject with a blood or serum CRP level of less than 10 mg / L. The disclosure also discloses the use of 1-MNA or a pharmaceutically acceptable salt thereof in the amount effective for reducing the blood or serum CRP level for the treatment of diseases such as rheumatoid arthritis, colon cancer, breast cancer, lung cancer, infection, inflammatory bowel disease, lupus erythematosus, pneumococcal pneumonia, rheumatic fever, tuberculosis, renal failure, amyotrophic lateral sclerosis,or a combination thereof.

Description

field of invention [0001] The present invention is in the field of treatment of diseases associated with C-reactive protein. Background of the invention [0002] 1-Methylnicotinamide (1-MNA) is a quaternary pyridinium compound. It is a metabolite of niacinamide. 1-MNA can exist in various pharmaceutically acceptable salt forms (eg 1-MNA chloride). [0003] C-reactive protein (CRP), a plasma protein synthesized by the liver, is a sensitive and dynamic marker of systemic inflammation. CRP is a ring-shaped acute-phase pentameric protein that triggers inflammation after secretion of interleukin-6 by macrophages and T cells, and CRP levels increase in response to inflammation. CRP binds to lysophosphatidylcholine expressed on the surface of dead or dying cells and certain types of bacteria, activating the complement system through the C1Q complex. Thompson, D. et al. "The physiological structure of human C-reactive protein and its complex with phosphocholine" Structure 7(2):1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/455A61K45/06A61K9/00A61P9/00A61P9/04A61P9/10A61P19/02A61P25/00A61P31/04A61P35/00A61P43/00A61P31/06
CPCA61K45/06A61K31/455A61P1/04A61P11/00A61P13/12A61P17/02A61P19/02A61P21/02A61P25/00A61P29/00A61P31/00A61P31/04A61P31/06A61P35/00A61P43/00A61P9/00A61P9/04A61P9/10A61P19/00A61K9/0053A61K31/465
Inventor K·帕尔卡J·格比基M·维佐科夫斯卡E·A·塞法利
Owner 法米娜生物技术公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com